Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 731

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 6
Chunk 731
---
 discount rate of 3.84%
– 3.99% based on the applicable US Treasury bill rate (2) expected life of 6.0 – 6.25 years, (3)
expected volatility of approximately 91% based on the trading history of similar companies, and (4) zero expected dividends.

At December 31, 2024, the Company had 121,243
shares reserved for issuance pursuant to the 2021 Amended and Restated Incentive Stock Plan and 15,975 shares available pursuant to the
2019 Stock Incentive Plan.

The following table summarizes stock option activity:

  (in thousands, except share and per share amounts)  Number of Shares   Weighted- average Exercise Price   Weighted- average Remaining Contractual Term (years)   Aggregate Intrinsic Value   Outstanding at December 31, 2022   4,841,417   $8.60    6.28    -   Options granted   665,000   $9.69    10.0    -   Options exercised   -   $-    -    -   Options cancelled   (10,417)  $12.44    -    -   Outstanding at December 31, 2023   5,496,000   $8.73    6.18    -   Options granted   1,964,307   $7.06    10.0    -   Options cancelled   (149,000)  $9.90    -    -   Options exercised   (108,000)  $3.91    -    -   Outstanding at December 31, 2024   7,203,307   $8.29    6.49   $1,218   Exercisable at December 31, 2024   4,988,685   $8.68    5.20   $1,218  

F-16

During the years ended December 31, 2024 and 2023, the Company
recognized stock-based compensation expense of $7,605,000 and $7,368,000, respectively, related to stock options. As